Cargando…

The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial

PURPOSE: Time of drug administration may significantly influence its effect. The aim of the present study was to investigate the effect of ASA (administrated in the morning or in the evening) on the anti-hypertensive effect and diurnal blood pressure profile in the high-risk group of cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasińska, Beata, Paluszkiewicz, Lech, Miciak-Ławicka, Ewa, Krasinski, Maciej, Rzymski, Piotr, Tykarski, Andrzej, Krasiński, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782434/
https://www.ncbi.nlm.nih.gov/pubmed/32959110
http://dx.doi.org/10.1007/s00228-020-02997-8
_version_ 1783631901634854912
author Krasińska, Beata
Paluszkiewicz, Lech
Miciak-Ławicka, Ewa
Krasinski, Maciej
Rzymski, Piotr
Tykarski, Andrzej
Krasiński, Zbigniew
author_facet Krasińska, Beata
Paluszkiewicz, Lech
Miciak-Ławicka, Ewa
Krasinski, Maciej
Rzymski, Piotr
Tykarski, Andrzej
Krasiński, Zbigniew
author_sort Krasińska, Beata
collection PubMed
description PURPOSE: Time of drug administration may significantly influence its effect. The aim of the present study was to investigate the effect of ASA (administrated in the morning or in the evening) on the anti-hypertensive effect and diurnal blood pressure profile in the high-risk group of cardiovascular patients. METHODS: All patients (n = 114) had been diagnosed with coronary heart disease and arterial hypertension prior to the enrolment and had been treated with 75 mg per day of ASA in the morning. The patients were randomly assigned to one of the two study groups receiving 75 mg of ASA per day in a single antiplatelet therapy for 3 months in the morning (n = 58) or in the evening (n = 56). The control group (n = 61) consisted of patients with arterial hypertension but without coronary heart disease, not receiving ASA. In all the patients, during each visit, clinical blood pressure (BP) and ambulatory blood pressure measurements (ABPM) were performed. RESULTS: There was a significant reduction in 24-h BP and blood pressure at night in the ASA group evening group compared with the ASA morning group and the control group. CONCLUSIONS: The present study demonstrated that compared with the use of ASA in the morning, its administration in the evening may lead to favourable drop in the ABPM and an improvement of the diurnal profile in the high-risk group of cardiovascular patients who are not naïve to ASA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-020-02997-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7782434
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-77824342021-01-11 The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial Krasińska, Beata Paluszkiewicz, Lech Miciak-Ławicka, Ewa Krasinski, Maciej Rzymski, Piotr Tykarski, Andrzej Krasiński, Zbigniew Eur J Clin Pharmacol Pharmacodynamics PURPOSE: Time of drug administration may significantly influence its effect. The aim of the present study was to investigate the effect of ASA (administrated in the morning or in the evening) on the anti-hypertensive effect and diurnal blood pressure profile in the high-risk group of cardiovascular patients. METHODS: All patients (n = 114) had been diagnosed with coronary heart disease and arterial hypertension prior to the enrolment and had been treated with 75 mg per day of ASA in the morning. The patients were randomly assigned to one of the two study groups receiving 75 mg of ASA per day in a single antiplatelet therapy for 3 months in the morning (n = 58) or in the evening (n = 56). The control group (n = 61) consisted of patients with arterial hypertension but without coronary heart disease, not receiving ASA. In all the patients, during each visit, clinical blood pressure (BP) and ambulatory blood pressure measurements (ABPM) were performed. RESULTS: There was a significant reduction in 24-h BP and blood pressure at night in the ASA group evening group compared with the ASA morning group and the control group. CONCLUSIONS: The present study demonstrated that compared with the use of ASA in the morning, its administration in the evening may lead to favourable drop in the ABPM and an improvement of the diurnal profile in the high-risk group of cardiovascular patients who are not naïve to ASA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-020-02997-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-09-21 2021 /pmc/articles/PMC7782434/ /pubmed/32959110 http://dx.doi.org/10.1007/s00228-020-02997-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Pharmacodynamics
Krasińska, Beata
Paluszkiewicz, Lech
Miciak-Ławicka, Ewa
Krasinski, Maciej
Rzymski, Piotr
Tykarski, Andrzej
Krasiński, Zbigniew
The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
title The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
title_full The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
title_fullStr The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
title_full_unstemmed The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
title_short The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
title_sort impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients—a randomized, controlled trial
topic Pharmacodynamics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782434/
https://www.ncbi.nlm.nih.gov/pubmed/32959110
http://dx.doi.org/10.1007/s00228-020-02997-8
work_keys_str_mv AT krasinskabeata theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT paluszkiewiczlech theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT miciakławickaewa theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT krasinskimaciej theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT rzymskipiotr theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT tykarskiandrzej theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT krasinskizbigniew theimpactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT krasinskabeata impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT paluszkiewiczlech impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT miciakławickaewa impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT krasinskimaciej impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT rzymskipiotr impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT tykarskiandrzej impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial
AT krasinskizbigniew impactofacetylsalicylicaciddosedatbedtimeoncircadianrhythmsofbloodpressureinthehighriskgroupofcardiovascularpatientsarandomizedcontrolledtrial